Description of Retatrutide from Wuhan Fortuna Chemical Co.,Ltd

Specifications(COA) of Retatrutide CAS 2381089-83-2

Introduction of Retatrutide is an investigational triple agonist drug targeting three receptors: GLP-1, GIP, and glucagon, developed for obesity and type 2 diabetes.

Mechanism: Mimics gut hormones to enhance insulin secretion, suppress appetite, and boost energy expenditure.

Efficacy: In Phase 2 trials, it demonstrated significant weight loss (up to ~24% of body weight at 48 weeks) and improved metabolic markers.

Development: Led by Eli Lilly, currently advancing to Phase 3 trials.

Potential: Aims to surpass existing GLP-1 drugs (e.g., semaglutide) by leveraging multi-receptor action for greater metabolic benefits.

Safety: Common side effects include gastrointestinal issues (nausea, diarrhea). Not yet FDA-approved; results remain under study.

Application of Retatrutide is an investigational peptide-based pharmaceutical drug developed by Eli Lilly and Company. It functions as a triple agonist, targeting three key receptors involved in metabolic regulation:

1.     GLP-1 (glucagon-like peptide-1): Enhances insulin secretion, suppresses appetite, and slows gastric emptying.

2.     GIP (glucose-dependent insulinotropic polypeptide): Modulates metabolism and fat storage.

3.     Glucagon receptor: Increases energy expenditure and may improve lipid metabolism.

Key Features:

Indications: Primarily being studied for obesity and type 2 diabetes mellitus.

Clinical Trials: Demonstrated promising results in Phase 2 trials (as of 2023), with participants experiencing up to 24% mean weight loss over 48 weeks, surpassing efficacy of existing GLP-1/GIP agonists like tirzepatide (Mounjaro?) and semaglutide (Wegovy?).

Administration: Subcutaneous injection, likely once weekly.

Mechanism: The triple-action approach aims to synergistically improve glycemic control and promote weight loss while potentially mitigating side effects through balanced receptor activation.

Safety Profile:

Common side effects include gastrointestinal issues (nausea, diarrhea, vomiting), consistent with other GLP-1-based therapies.

Ongoing Phase 3 trials will further assess long-term safety and efficacy.

Development Status:

Expected to advance through Phase 3 trials, with potential FDA approval for obesity and diabetes in the coming years. If approved, it could become a leading option for patients requiring significant metabolic improvement.

Retatrutide represents a novel approach in metabolic therapeutics, highlighting the trend toward multi-targeted therapies for complex conditions like obesity and diabetes.

Wuhan Fortuna Chemical Co.,Ltd established in 2006, is a big integrative chemical enterprise being engaged in Pharmaceutical and Intermediates, Food and Feed additives, Fine chemicals,Biochemical and Reagent, which is  the members of Hubei E-commerce Chamber.

Our company has professional persons who major in chemical R&D and sicentific management, supply fine chemical products with high quality and close service, also supply custom-tailored products according to our clients' requirement.

We have a positive and self-motivated management work team with a common philosophy, caring and commitment through teamwork, our team strive to achieve success in delighting our clients and ourselves.

Since Wuhan Fortuna Chemical Co., Ltd founded, we continuously innovate our products and improve our service, sales network. Hence, we initiate the first sale mode on net in China, which is the retail trade of small package bring along wholesale of diversified management modes. Our products are exported widely to South Korea, Vietnam, Australia, Europe and South America, highly recommended by our clients.We insist on the management creed “Market is our compass, Quality is our life, Credit is our soul”. Clients’ trust is our forward power, their satisfaction is our struggling goal.

Wuhan Fortuna Chemical Co.,Ltd is a professional manufacturer which provide Retatrutide with good quality and best price, welcome to contact us to get COA/TDS/MSDS of Retatrutide.